Medicine Overview
Adult Dose
| Clinical Information | Administration Information |
|---|---|
|
Indication: Rheumatoid arthritis, Ankylosing spondylitis, Psoriatic arthritis Age: Adult |
Dose: Subcutaneous Injection – 40 mg Frequency: once every other week Note: Some patients with rheumatoid arthritis not receiving methotrexate may benefit from increasing the frequency to 40 mg every week. |
|
Indication: Crohn's disease, Ulcerative colitis Age: Adult Condition: Moderate to severely active disease (Initial Dose) |
Dose: Subcutaneous Injection – 160 mg Frequency: once (given as four 40-mg injections in 1 day or as two 40-mg injections for 2 consecutive days) Duration: Day 1 |
Child Dose
| Clinical Information | Administration Information |
|---|---|
|
Indication: Juvenile idiopathic arthritis Age: Child |
Dose: Subcutaneous – Safety and efficacy not established Note: Safety and efficacy not established |
|
Indication: Juvenile idiopathic arthritis Age: greater than 2 years |
Dose: Subcutaneous – 10 mg Frequency: every other week |
Administration
- Given as subcutaneous injection
- Rotate injection sites
Side Effect
- Injection site pain (12-20%)
- Upper respiratory tract infection (URTI) (URTI) (17%)
- Increased creatine phosphokinase (15%)
- Headache (12%)
- Rash (12%)
- Sinusitis (11%)
- Nausea (9%)
- Urinary Tract Infection (UTI) (8%)
- Abdominal pain (7%)
- Flulike syndrome (7%)
- Hyperlipidemia (7%)
- Back pain (6%)
- Hypercholesterolemia (6%)
- Hematuria (5%)
- Hypertension (5%)
- Increased alkaline phosphatase (5%)
- Allergic reactions
- Hematologic disorder (leukopenia, thrombocytopenia, pancytopenia, aplastic anemia)
- Sepsis
- opportunistic infections
- TB
- HBV reactivation
- other malignancies (eg leukaemia, lymphoma, hepatosplenic T-cell lymphoma)
- haematological
- neurological and autoimmune reactions
- anaphylaxis
- angioneurotic oedema
Drug Interaction
Drug Interaction
| Drug Name | Risk Factors |
|---|---|
|
Other biologic disease-modifying antirheumatic drugs (e.g. abatacept, anakinra), rituximab
|
Increased risk of serious infections
|
|
Tocilizumab, live vaccines
|
May increase immunosuppressant effect
|
Disease Interaction
Disease Interaction
| Disease Name | Risk Factors |
|---|---|
|
No specific contraindications listed
|
Monitor for general reactions
|
Pregnancy
Pregnancy
Lactation
Special Use
Precaution
Overdose
Pharmacology
Storage
Do not use beyond the expiration date on the container. Adalimumab must be refrigerated at 2-8° C. Do not freeze. Protect the pre-filled syringe from exposure to light. Store in original carton until time of administration.
Data Sources
Clinical & regulatory information on this page is compiled from the following government sources:
DISCLAIMER: This drug information content is provided for informational purposes only and is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Patients should always consult their physician with any questions regarding a medical condition and to obtain medical advice and treatment.